A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants With Chronic Hepatitis B Infection (PREVAIL)
Sponsor: Vir Biotechnology, Inc.
A PHASE1/PHASE2 clinical study on Hepatitis B, Chronic, this trial is completed. The trial is conducted by Vir Biotechnology, Inc. and has accumulated 13 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE1/PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
▶ Show 8 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2023 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vir Biotechnology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bucharest, Romania , Busan, South Korea , Chisinau, Moldova , Clichy, France , Glasgow, United Kingdom , Hong Kong, Hong Kong , London, United Kingdom , Manchester, United Kingdom , Nice, France , Rennes, France and 3 more locations